Intravitreal implants in conjuction with photodynamic therapy to improve vision

• US 20050244500A1
• Filed: 04/22/2005
• Published: 11/03/2005
• Est. Priority Date: 04/30/2004
• Status: Abandoned Application

• Current Assignee: Allergan Incorporated (Abbvie Incorporated)
• Original Assignee: Allergan Incorporated (Abbvie Incorporated)
• Inventors: Weinberg, David A., Whitcup, Scot M., Burke, James A.
• Application Number:
  US11/112,523
• Publication Number:
  US 20050244500A1
• Time in Patent Office: Days
• US Class Current: 424/486
• CPC Class Codes: A61K 9/0009 involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis microelectromechanical systems A61K9/0097
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: A61P 27/02 Ophthalmic agents

Abstract

A method for treating a posterior ocular condition so as to improve vision is provided. The method includes the steps of placing into an eye, a bioerodible implant comprising an anti-inflammatory component and a bioerodible polymeric component, introducing a photoactive agent into the eye, and irradiating the eye with electromagnetic radiation, for example light energy, in order to activate the photoactive agent in the eye and treat the posterior ocular condition, thereby improving a patient'"'"'s vision.

Claims

1. A method for improving vision, the method comprising the steps of:

(a) placing into the vitreous of an eye of a patient with macular degeneration a biodegradable implant comprising a poly lactic acid poly glycolic acid copolymer (PLGA) and an anti-inflammatory active agent associated with the PLGA;

(b) introducing a photoactive agent into the eye, and;

(c) irradiating the eye to activate the photoactive agent, thereby treating the macular degeneration and improving the patient'"'"'s vision.

2. The method of claim 1 wherein the photoactive agent comprises porphyrin.

3. The method of claim 1 wherein the photoactive agent comprises verteporfin.

4. The method of claim 1 wherein the photoactive agent is selected from the group consisting of hematoporphyrins, hematoporphyrin derivatives, pheophorbides, derivatives of pheophorbides, bacteriochlorins, purpurins, merocyanines, porphycenes, and combinations thereof.

5. The method of claim 1 wherein the active agent is a steroid.

6. The method of claim 1 wherein the anti-inflammatory active agent is selected from the group consisting of cortisone, dexamethasone, fluocinolone, hydrocortisone, methylprednisolone, prednisolone, prednisone, and triamcinolone, derivatives thereof and mixtures thereof.

7. The method of claim 1 wherein the anti-inflammatory active agent is selected from the group consisting of corticosteroids and mixtures thereof.

8. The method of claim 5 wherein the steroid is dexamethasone.

9. The method of claim 1 wherein the step of introducing a photoactive agent comprises intravenously introducing the photoactive agent.

12. The method of claim 5 wherein the steroid is dexamethasone.

11. A method for improving vision, the method comprising the steps of:

(a) placing into the vitreous of an eye of a patient with macular degeneration a biodegradable implant comprising a polylactic acid, polyglycolic acid copolymer (PLGA) and an anti-inflammatory steroid associated with the PLGA;

(b) intravenously introducing a porphyrin photoactive agent into the eye, and;

(c) irradiating the eye to activate the photoactive agent, thereby treating the macular degeneration and improving the patient'"'"'s vision.

13. A method for treating subfoveal choroidal neovascularization, the method comprising the steps of:

(a) placing into the vitreous of an eye of a patient with subfoveal choroidal neovascularization a biodegradable implant comprising a polylactic acid, polyglycolic acid copolymer (PLGA) and dexamethasone associated with the PLGA;

(b) intravenously introducing a porphyrin photoactive agent into the eye, and;

(c) irradiating the eye to activate the photoactive agent, thereby treating the subfoveal choroidal neovascularization by reducing the incidence of the subfoveal choroidal neovascularization in the eye of the patient by an amount greater than the reduction of an incidence of subfoveal choroidal neovascularization in a reference eye upon which a method comprising only step (a) or only steps (b) and (c) has been practised.